Corporate communications

August 10, 2023 TORONTO, Canada and RIONEGRO, Colombia (August 10, 2023) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today provided

TORONTO, Canada and RIONEGRO, Colombia (July 11, 2023) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today announced that Marc Lustig

Jun 29, 2023 PharmaCielo Provides Corporate Update PharmaCielo is actively working with more than 24 customers in 15 countries globally, with a focus on psychoactive APIs and dried flower. The Company recently made its first shipment of THC Distillate and THC-Dominant Dried Flower to a

July 24, 2023 One of the largest production capacities in the world at great efficiency and world wide presence . Unique cannabis genetics, deep cultivar library, expert agronomy and equatorial growing conditions . Pharma approach for consistent quality: GACP, ICANN GAP and EUGMP standards for

May 29, 2023 The Company has products in various stages of testing and sales with more than 40 customers in 11 countries, with continued growth expected for the year. Q1 2023 revenue of $786,498; Adjusted EBITDA loss of $1.9 million. PharmaCielo continues to focus on

May 16, 2023 Represents PharmaCielo’s first shipment to South Africa, which has well-established export networks in the UK and Australia, and other potential markets, globally. TORONTO, Canada and RIONEGRO, Colombia (May 16, 2023) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the

May 1, 2023  During 2022, PharmaCielo made shipments to 23 clients in 9 countries, with continued growth expected for 2023. The Company’s measured investments in revenue-generating sales channels resulted in revenues of $5.3 million in 2022, almost three-times more than the $1.9 million reported in

April 19, 2023 Will bring unique high-THC Colombian strains owned by PharmaCielo to Europe for the first time. Combines PharmaCielo’s expertise in producing premium medicinal cannabis products, with CANNPRISMA’s conversion capabilities, to bring patients in Europe the highest quality high-THC flower product currently available in

February 8, 2023 PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in Brazil (the “Customer”), for final testing. The Customer has already qualified PharmaCielo as a supplier of API – the Company